Novo Nordisk shares climb after positive anti-obesity pill results

Novo Nordisk's shares jumped over 6% (£9bn) after clinical trial results for its new oral anti-obesity drug demonstrated significant weight loss, comparable to its injectable Wegovy. This development positions Novo Nordisk to potentially reclaim market share against competitor Eli Lilly and generic GLP-1s, especially as it becomes the first to submit an oral GLP-1 to the FDA, with a decision anticipated by year-end. The convenience and expected lower cost of a pill format could significantly expand the anti-obesity market, intensifying competition with Eli Lilly's similar drug, which analysts project for substantial peak sales.

Analysis

Novo Nordisk's valuation increased by approximately £9bn, with its shares surging over 6%, following the release of positive late-stage clinical trial data for its oral anti-obesity pill. The study demonstrated significant efficacy, with patients achieving an average body weight loss of 16.6% over 64 weeks, a result nearly comparable to its injectable Wegovy. This development is pivotal for Novo, which had seen its stock fall nearly 60% over the past year amid slowing sales and profit warnings, as it positions the company to reclaim market share from its primary competitor, Eli Lilly. Novo has become the first to submit an oral GLP-1 drug to the FDA, with a regulatory decision anticipated by year-end. The competitive landscape remains intense, with Eli Lilly's oral drug, orforglipron, showing a 12.4% average weight loss in a larger trial. While a UBS analyst sees 'clear leadership' for Novo's pill with peak sales forecast at $5bn, Eli Lilly's drug is considered a threat due to potential advantages in scalability, pricing, and convenience, as it does not require a fasting period. Analyst estimates for Lilly's drug are substantially higher, with Jefferies projecting peak sales of $10bn to $25bn. The shift to a cheaper, more accessible pill format is expected to significantly expand the total addressable market for anti-obesity treatments.

Key Decisions for Investors

• Investors should view this data as a significant de-risking event for Novo Nordisk's pipeline, with the upcoming FDA decision by year-end serving as the primary near-term catalyst that could reverse the stock's recent underperformance.
• While Novo Nordisk has a potential first-mover advantage in the oral segment, Eli Lilly's orforglipron presents a formidable long-term threat due to its potential for greater manufacturing scale, lower pricing, and superior convenience, which could drive market share.
• The key long-term determinant of value in the oral obesity market will be manufacturing capacity and pricing strategy; therefore, investors should closely monitor commentary from both companies on production ramp-ups and go-to-market pricing for these new tablet formulations.